Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Ordinary Shares, par value CHF 0.10 per share
-
Shares outstanding
-
41.7M
-
Number of holders
-
12
-
Total shares
-
3.49M
-
Shares change
-
+480K
-
Total reported value, excl. options
-
$59.4M
-
Value change
-
+$8.16M
-
Number of buys
-
8
-
Number of sells
-
-1
-
Price
-
$17.00
Significant Holders of Oculis Holding AG - Ordinary Shares, par value CHF 0.10 per share (OCS) as of Q4 2024
13 filings reported holding OCS - Oculis Holding AG - Ordinary Shares, par value CHF 0.10 per share as of Q4 2024.
Oculis Holding AG - Ordinary Shares, par value CHF 0.10 per share (OCS) has 12 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.49M shares
of 41.7M outstanding shares and own 8.38% of the company stock.
Largest 10 shareholders include Pivotal bioVenture Partners Investment Advisor LLC (1.74M shares), abrdn plc (1.01M shares), Nan Fung Group Holdings Ltd (436K shares), UBS Group AG (109K shares), Compagnie Lombard Odier SCmA (95.8K shares), BANK OF AMERICA CORP /DE/ (29K shares), CITADEL ADVISORS LLC (22.9K shares), GEODE CAPITAL MANAGEMENT, LLC (16.7K shares), NORTHERN TRUST CORP (13.6K shares), and XTX Topco Ltd (13.2K shares).
This table shows the top 12 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.